The future of AI drug discovery & development in immunology and GPCR research

The future of AI drug discovery & development in immunology and GPCR research

Source: PharmaPhorum

By Nicole Raliegh

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares.A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic targeting in immune-mediated disease”. Now, Verily has announced that early results from its “next generation immune mapping technology” Immune Profiler platform have already identified “more effective therapeutic options against G protein-coupled receptors (GPCR) in autoimmune and other immune-mediated diseases”.Keep reading...